Albumin is efficiently taken up und degradedby cancer cells due to their enhanced needs for nutrients.25 In the second axial position, the clinicallyinvestigated IDO inhibitor 1-MDT was attached.8 This approach results in the tumor-specific release of the immunomodulatortogether with oxaliplatin after activation by reduction inside thecancer cell. The gene discussed is IDO1; the disease is neoplasm.